{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:38:45Z","timestamp":1781602725862,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11912-022-01324-x","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T07:03:00Z","timestamp":1660978980000},"page":"1695-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology"],"prefix":"10.1007","volume":"24","author":[{"given":"Lodovico","family":"Balducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"issue":"7","key":"1324_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","volume":"81","author":"S Dhillon","year":"2021","unstructured":"\u2022\u2022 Dhillon S, et al. Drugs. 2021;81(7):867\u201374. https:\/\/doi.org\/10.1007\/s40265-021-01508-y. This article explains the mechanism of action of trilaciclib and the potential limitation of its use.","journal-title":"Drugs"},{"issue":"10314","key":"1324_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"\u2022\u2022 Mohile SG, Mohamed MR, Xu H, Culakova E, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(21)01789-X. Important for two reasons: it demonstrates the feasibility of geriatric assessment in the clinical practice of oncology and the ability of the geriatric assessment to ameliorate the risks of chemotherapy.","journal-title":"Lancet"},{"issue":"11","key":"1324_CR3","doi-asserted-by":"publisher","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","volume":"7","author":"D Li","year":"2021","unstructured":"Li D, Sun CL, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):e214158. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4158.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1324_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/0284186X.2012.744142","volume":"52","author":"L Balducci","year":"2013","unstructured":"Balducci L, Fossa SD. Rehabilitation of older cancer patients. Acta Oncol. 2013;52(2):233\u20138. https:\/\/doi.org\/10.3109\/0284186X.2012.744142.","journal-title":"Acta Oncol"},{"key":"1324_CR5","unstructured":"https:\/\/cancercontrol.cancer.gov\/ocs\/statistics#footnote1"},{"issue":"1","key":"1324_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12877-021-02722-9","volume":"22","author":"KF Boreskie","year":"2022","unstructured":"Boreskie KF, Hay JL, Boreskie PE, Arora RC, Duhamel TA. Frailty-aware care: giving value to frailty assessment across different healthcare settings. BMC Geriatr. 2022;22(1):13. https:\/\/doi.org\/10.1186\/s12877-021-02722-9.","journal-title":"BMC Geriatr"},{"issue":"5","key":"1324_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ctrv.2005.04.012","volume":"31","author":"I Carreca","year":"2005","unstructured":"Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31(5):380\u2013402. https:\/\/doi.org\/10.1016\/j.ctrv.2005.04.012.","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"1324_CR8","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1324_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897\u2013904. https:\/\/doi.org\/10.1007\/s00277-010-0956-7.","journal-title":"Ann Hematol"},{"issue":"1","key":"1324_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10\u20135. https:\/\/doi.org\/10.1056\/NEJM198101013040103.","journal-title":"N Engl J Med"},{"issue":"6","key":"1324_CR11","first-page":"541","volume":"84","author":"Y Beguin","year":"1999","unstructured":"Beguin Y. Erythropoietin and platelet production. Haematologica. 1999;84(6):541\u20137.","journal-title":"Haematologica."},{"issue":"6893","key":"1324_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/418025a","volume":"418","author":"SH Orkin","year":"2002","unstructured":"Orkin SH, Morrison SJ. Stem-cell competition. Nature. 2002;418(6893):25\u20137. https:\/\/doi.org\/10.1038\/418025a.","journal-title":"Nature."},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"\u2022\u2022 Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.\u00a0This reference describes the nexus of chemotherapy, growth factors, and MDS\/AML.","journal-title":"Nat Genet"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/blood.2019003539","volume":"135","author":"CW Eskelund","year":"2020","unstructured":"Eskelund CW, Husby S, Favero F, et al. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after the end of chemotherapy in patients with MCL. Blood. 2020;135:2000\u20134.","journal-title":"Blood"},{"issue":"4","key":"1324_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.seminhematol.2008.06.001","volume":"45","author":"L Ferrucci","year":"2008","unstructured":"Ferrucci L, Balducci L. Anemia of aging: the role of chronic inflammation and cancer. Semin Hematol. 2008;45(4):242\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.06.001.","journal-title":"Semin Hematol"},{"issue":"12","key":"1324_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/gerona\/63.12.1389","volume":"63","author":"SE Hardy","year":"2008","unstructured":"Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol A Biol Sci Med Sci. 2008;63(12):1389\u201392. https:\/\/doi.org\/10.1093\/gerona\/63.12.1389.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"1324_CR17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/j.1532-5415.2008.01957.x","volume":"56","author":"SE Hardy","year":"2008","unstructured":"Hardy SE, Studenski SA. Fatigue predicts mortality in older adults. J Am Geriatr Soc. 2008;56(10):1910\u20134. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01957.x.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1324_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","volume":"14","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437\u201348. https:\/\/doi.org\/10.1080\/17474086.2021.1924053.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"1324_CR19","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/cncr.20688","volume":"101","author":"C Borg","year":"2004","unstructured":"Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004;101(11):2675\u201380. https:\/\/doi.org\/10.1002\/cncr.20688.","journal-title":"Cancer."},{"issue":"4","key":"1324_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4103\/2141-9248.122054","volume":"3","author":"S Ocheni","year":"2013","unstructured":"Ocheni S, Ibegbulam O, Aguwa E, Madu K. Pattern of CD4 T-lymphocyte values in cancer patients on cytotoxic therapy. Ann Med Health Sci Res. 2013;3(4):498\u2013503. https:\/\/doi.org\/10.4103\/2141-9248.122054.","journal-title":"Ann Med Health Sci Res"},{"issue":"3","key":"1324_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JOP.19.00652","volume":"16","author":"TJ GBrown","year":"2020","unstructured":"\u2022 GBrown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. JCO Oncol Pract. 2020;16(3):103\u20139. https:\/\/doi.org\/10.1200\/JOP.19.00652. Review of current management of chemotherapy-induced mucositis.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"1324_CR22","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1324_CR23","first-page":"937","volume":"84","author":"G Leone","year":"1999","unstructured":"Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937\u201345.","journal-title":"Haematologica."},{"issue":"suppl_5","key":"1324_CR24","doi-asserted-by":"publisher","first-page":"S1164","DOI":"10.1016\/annonc\/annonc68","volume":"32","author":"Z Andric","year":"2021","unstructured":"Andric Z, Ceric T, Turic M, et al. A phase I b study of the dual MDMX\/MDM2 inhibitor for prevention of chemotherapy induced myelosuppression. Presented at the virtual European Society of Medical Oncology congress September 16 2021 #1654 AP. Ann Oncol. 2021;32(suppl_5):S1164\u201374. https:\/\/doi.org\/10.1016\/annonc\/annonc68.","journal-title":"Ann Oncol"},{"issue":"10","key":"1324_CR25","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol. 2019;30(10):1613\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdz278.","journal-title":"Ann Oncol"},{"issue":"10","key":"1324_CR26","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33453","volume":"148","author":"D Daniel","year":"2020","unstructured":"Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. 2020;148(10):2557\u201370. https:\/\/doi.org\/10.1002\/ijc.33453.","journal-title":"Int J Cancer"},{"issue":"1","key":"1324_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350\u201365. https:\/\/doi.org\/10.1007\/s12325-020-01538-0.","journal-title":"Adv Ther"},{"issue":"2","key":"1324_CR28","doi-asserted-by":"publisher","first-page":"e000847","DOI":"10.1136\/jitc-2020-000847","volume":"8","author":"AY Lai","year":"2020","unstructured":"Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020;8(2):e000847. https:\/\/doi.org\/10.1136\/jitc-2020-000847.","journal-title":"J Immunother Cancer"},{"key":"1324_CR29","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S313045","volume":"13","author":"M Hussein","year":"2021","unstructured":"\u2022\u2022 Hussein M, Maglakelidze M, Richards DA, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 2021;13:6207\u201318. https:\/\/doi.org\/10.2147\/CMAR.S313045. This article presents the pooled analysis of three studies and demonstrates the ability of trilaciclib to prevent thrombocytopenia and anemia in addition to neutropenia.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"1324_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, Goldschmidt J, Andric, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449\u201360. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010.","journal-title":"Clin Lung Cancer"},{"key":"1324_CR31","unstructured":"Gheradini et al. Temporary cell cycle arrest by ALRN-6924 selectively protects human scalp hair follicles and their epithelial cells from taxane-induced toxicity. Presented at the 2022 Society for Investigative Dermatology Annual Meeting"},{"issue":"10","key":"1324_CR32","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"\u2022 Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1540. Increase production of T-cell clones may be beneficial for treatment with immunotherapy.","journal-title":"Cancer Discov"},{"key":"1324_CR33","doi-asserted-by":"publisher","unstructured":"Zhou X, Singh M, Sanz Santos G, et al. Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discov. 2021:candisc.1741.2020. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1741.","DOI":"10.1158\/2159-8290.CD-20-1741"},{"issue":"sup1","key":"1324_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13696998.2021.2014163","volume":"24","author":"I Abraham","year":"2021","unstructured":"Abraham I, Onyekwere U, Deniz B, et al. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. J Med Econ. 2021;24(sup1):71\u201383. https:\/\/doi.org\/10.1080\/13696998.2021.2014163.","journal-title":"J Med Econ"},{"key":"1324_CR35","doi-asserted-by":"publisher","first-page":"697908","DOI":"10.3389\/fonc.2021.697908","volume":"11","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Kuderer NM, Aapro M. Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. Front Oncol. 2021;11:697908. https:\/\/doi.org\/10.3389\/fonc.2021.697908.","journal-title":"Front Oncol"},{"issue":"24","key":"1324_CR36","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","volume":"32","author":"A Hurria","year":"2014","unstructured":"Hurria A, Dale W, Mooney M, et al. Cancer and aging research group. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587\u201394. https:\/\/doi.org\/10.1200\/JCO.2013.55.0418.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1324_CR37","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","volume":"33","author":"A Hurria","year":"2015","unstructured":"Hurria A, Levit LA, Dale W, Mohile SG, et al. American Society of Clinical Oncology. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J Clin Oncol. 2015;33(32):3826\u201333. https:\/\/doi.org\/10.1200\/JCO.2015.63.0319.","journal-title":"J Clin Oncol"},{"issue":"38","key":"1324_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/EDBK_201133","volume":"23","author":"H Singh","year":"2018","unstructured":"Singh H, Hurria A, Klepin HD. Progress through collaboration: an ASCO and U.S. Food and Drug Administration Workshop to improve the evidence base for treating older adults with cancer. Am Soc Clin Oncol Educ Book. 2018;23(38):392\u20139. https:\/\/doi.org\/10.1200\/EDBK_201133.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"1324_CR39","doi-asserted-by":"publisher","first-page":"e0238890","DOI":"10.1371\/journal.pone.0238890","volume":"15","author":"H Jia","year":"2020","unstructured":"Jia H, Lubetkin EI. Life expectancy and active life expectancy by disability status in older U.S. adults. PLoS One. 2020;15(9):e0238890. https:\/\/doi.org\/10.1371\/journal.pone.0238890.","journal-title":"PLoS One"},{"issue":"13","key":"1324_CR40","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377\u201386. https:\/\/doi.org\/10.1002\/cncr.26646.","journal-title":"Cancer."},{"issue":"20","key":"1324_CR41","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","volume":"34","author":"A Hurria","year":"2016","unstructured":"Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366\u201371. https:\/\/doi.org\/10.1200\/JCO.2015.65.4327.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s11912-022-01336-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000}}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01324-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T14:11:05Z","timestamp":1669903865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01324-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01324-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"28 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11912-022-01336-7","URL":"https:\/\/doi.org\/10.1007\/s11912-022-01336-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lodovico Balducci is consultant for Aileron therapeutic.Claire Falandry has received research funding from Chugai Pharmaceutical Co., Ltd., Pfizer, Astellas Pharma, and Laboratoires Pierre Fabre; has received speaker's honoraria from Leo Pharma, Pfizer, MSD Oncology, Janssen Oncology, Teva Pharmaceuticals, AstraZeneca, Baxter International, Eisai, Novartis, Chugai Pharmaceutical Co., Ltd., and Astellas Pharma; has received travel support from Janssen Oncology, GSK Oncology, Laboratoires Pierre Fabre, AstraZeneca, and Leo Pharma.Alan List has received compensation for service as a consultant from Aileron Therapeutics, and also has stock options in Aileron Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies of human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}